Method for treating rheumatoid arthritis with a human il-6 receptor antibody and methotrexate
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsOsamu Okuda, Noriaki Yoshida, Ravinder Nath Maini
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R).
Claims23
-15. (canceled)
A method for treating rheumatoid arthritis in a patient, comprising administering to a patient a combination of (i) 4 mg/kg or 8 mg/kg of a humanized anti-interleukin-6 receptor (anti-IL-6R) antibody MRA every four weeks and (ii) methotrexate (MTX).
A method for treating rheumatoid arthritis in a patient, comprising administering to a patient a combination of (i) 4 mg/kg or 8 mg/kg of a humanized anti-interleukin-6 receptor (anti-IL-6R) antibody humanized PM-1 (hPM-1) every four weeks and (ii) methotrexate (MTX).
Dependencies are inferred from the claim text.